12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers Cadrenal Therapeutics (NASDAQ:CVKD) stock rose 22.5% to $1.58 during Friday’s after-market session. This security traded at a…
Why Senmiao Technology Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Gainers
Jiuzi Holdings, Inc. (NASDAQ: JZXN) shares surged 106.8% to $5.77 in pre-market trading. The stock began trading on a 1:18 reverse split on July 10.
AIM ImmunoTech Enrolls And Doses First Subject In Phase 2 Study Evaluating Ampligen For The Treatment Of Post-COVID Conditions
Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions
Enrollment expected to be completed in Q4 2023
OCALA, Fla., July 10, 2023 (GLOBE NEWSWIRE)
Why Tivic Health Systems Are Trading Lower By 23%; Here Are 20 Stocks Moving Premarket
Gainers
Nanobiotix S.A. (NASDAQ: NBTX) shares surged 59.3% to $8.02 in pre-market trading after the company entered into a license agreement with Janssen Pharmaceutical for global co-development and commercialization of NBTXR3.
Why VBI Vaccines Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket
Gainers
Akumin Inc. (NASDAQ: AKU) shares surged 58.2% to $0.2865 in pre-market trading. Akumin recently named Krishna Kumar as President and Chief Operating Officer of the Company.
Why CorMedix Are Trading Lower By 22%; Here Are 20 Stocks Moving Premarket
Gainers
Eco Wave Power Global AB (NASDAQ: WAVE) shares surged 123% to $3.48 in pre-market trading after dropping over 8% on Wednesday.
AIM ImmunoTech Announces Publication Of Findings from A Pre-Clinical Study Evaluating Ampligen In The Treatment Of Pancreatic Cancer In The American Journal Of Cancer Research
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of its TLR-3 agonist Ampligen (rintatolimod) as a novel and
AIM ImmunoTech Announces Authorizations From Competent Authority And Ethics Board In The Netherlands To Begin A Phase 1b/2 Study Evaluating Ampligen In Combination With AstraZeneca’s Imfinzi For The Treatment Of Pancreatic Can
Ampligen has shown therapeutic synergies with checkpoint inhibitors, potentially increasing survival rates and efficacy
Patient enrollment expected to commence before the end of 2023
OCALA, Fla., June 27, 2023 (GLOBE
Why Oncorus Shares Are Trading Lower By 25%; Here Are 20 Stocks Moving Premarket
Gainers
Auddia Inc. (NASDAQ: AUUD) shares rose 103.2% to $0.8809 in pre-market trading after gaining around 9% on Friday.
Earnings Preview: AIM ImmunoTech
AIM ImmunoTech (AMEX:AIM) is set to give its latest quarterly earnings report on Tuesday, 2023-05-16. Here’s what investors…